Koichi Azuma

17PUBLICATIONS
82CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersImmunogenetics (incl. genetic immunology)Medical biochemistry - amino acids and metabolites
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|May 26, 2026
Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in Patients with Locally Advanced NSCLC.

|Mar 11, 2026
Constitutive EGFR Activation Induced by PTPRR Downregulation Confers Resistance to KRAS Inhibitors.

Hiroaki Kanemura, Toshiyuki Takehara, Osamu Maenishi

|Mar 31, 2025
Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non-Small Cell Lung Cancer Harboring EGFR Mutation.

Shintaro Kanda, Seiji Niho, Takayasu Kurata

|Sep 05, 2024
Characterization of pre- and on-treatment soluble immune mediators and the tumor microenvironment in NSCLC patients receiving PD-1/L1 inhibitor monotherapy.

Daiki Murata, Koichi Azuma, Kenta Murotani

|Jan 05, 2024
Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort.

Makoto Nishio, Shuji Murakami, Hisato Kawakami

|Sep 15, 2023
Survival and biomarkers for cachexia in non-small cell lung cancer receiving immune checkpoint inhibitors.

Daiki Murata, Koichi Azuma, Norikazu Matsuo

Pageof 3

Frequent Collaborators

4 joint publications

Takaaki Tokito

4 joint publications

Daiki Murata

2 joint publications

Haruyasu Murakami

2 joint publications

Makoto Nishio